Long-term results of combined and complex treatment of patients with locally advanced HER2-positive breast cancer

The study included 73 women with stage III HER2-positive locally advanced breast cancer (BC) who received simultaneous chemoradiotherapy in combination with targeted therapy. Patients were stratified into two groups: in patients from the first group in the neoadjuvant setting received concomitant chemoradiotherapy in combination with trastuzumab, in the second group patients did not receive no targeted therapy. The therapy with trastuzumab appeared to be the most effective regarding overall survival. 3-year survival rate in the first group was 85.5 %, in the second group - 73.3 %, 5-year survival rate was 73.9 % and 40.3 %, respectively (p